Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Incyte Corp

INCY ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$121.47

▼ -1.47%

Market Cap $24.62B · Vol 622.30K

Key Metrics

P/E Ratio

15.48

FWD: 17.11

Market Cap

$24.62B

Large Cap

Div Yield

N/A

EPS Growth

-48.89%

YoY

RSI (14)

37.11

Momentum

Beta

0.74

vs Market

52W High

$132.58

8.38% below

52W Low

$81.09

49.80% above

Volume

622.30K

Avg 522.41K

P/B

3.79

Price-to-book

ROE

31.70%

Return on equity

Free Float

98.03%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Incyte Corp (INCY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INCY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.10%

+0.33%

+12.65%

+28.32%

YTD

+22.98%

+40.97%

+89.12%

+70.80%

Financials & Valuation

TTM · Annual

Total Revenue	$5.14B
Net Income	$1.29B
Revenue Growth (YoY)	+37.72%
Gross Margin	92.76%
Operating Margin	26.12%
Net Profit Margin	25.03%
ROE	31.70%
ROA · ROIC	26.84% · 29.66%

P/E Ratio	15.48
Forward P/E (FY1)	17.11
PEG Ratio	0.00
P/S	3.86
P/B	3.79
P/FCF	14.91
EPS Growth	-48.89%
Outstanding Shares	202.70M

Technical Indicators

50-Day SMA	$121.60
200-Day SMA	$105.15
RSI (14)	37.11
Beta	0.74
52-Week High	$132.58
52-Week Low	$81.09

Volume Today	622.30K
Avg Daily Volume (30D)	522.41K
Relative Volume	1.19x
Volatility (10D)	27.45
Volatility (30D)	25.67
Free Float	98.03%

Analyst Consensus

BUY

Current Price $121.47

Mean Target $127.51

52W Low$81.09 52W High$132.58

Current

Target

$81.09 $132.58

Current Analyst target

+4.97% upside potential · 28 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S8Q6N2

ISINUS45337C1027

CountryUSA

Sub-IndustryBiopharmaceuticals

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. -1.48% CSL.AX CSL Limited -1.42% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. -0.56% UCB.BR Ucb SA +1.93% BIIB Biogen Inc. +0.80%

Company Profile

Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.